Illumina
ILMN
$215.59
-5.31%
Illumina Inc. is a global leader in DNA sequencing and array-based technologies, providing instruments, consumables, and services that enable genomic analysis for research, clinical, and applied markets. The company's high-throughput sequencing platforms dominate the market, with over 90% of revenue derived from sequencing-related products, while microarrays contribute the remainder. Illumina is currently at the center of investor attention due to its strategic focus on expanding clinical applications, particularly through its spin-off Grail and its Galleri multi-cancer screening test, despite recent clinical trial setbacks. The stock has seen a dramatic re-rating in 2026, driven by strong revenue growth, margin expansion, and optimism about the adoption of genomic tools in healthcare.…
ILMN
Illumina
$215.59
Related headlines
Investment Opinion: Should I buy ILMN Today?
Based on the analysis, ILMN is rated a Hold. The consensus recommendation is 'Buy' with an average target of $198.89, but the current price of $219.40 is 9.3% above this target, suggesting limited upside. The thesis is that while Illumina's dominant market position and strategic initiatives are promising, the stock has outpaced fundamental estimates, making it a hold rather than a buy at current levels.
Sign up to view all
ILMN 12-Month Price Forecast
The AI model assesses ILMN as neutral, reflecting a balance between strong operational metrics and stretched valuation. The stock's momentum is impressive, but the forward PE and negative PEG ratio suggest that earnings expectations are not supportive of the current price. The model would upgrade to bullish if revenue growth accelerates above 10% and the forward PE compresses below 30x, or downgrade to bearish if Grail fails or revenue growth falls below 3%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Illumina's 12-month outlook, with a consensus price target around $198.89 and implied upside of -7.7% versus the current price.
Average Target
$198.89
0 analysts
Implied Upside
-7.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$113 - $230
Analyst target range
Illumina is covered by 19 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 2.45 (where 1 is Strong Buy and 5 is Sell). The average price target is $198.89, which is 9.3% below the current price of $219.40, implying a downside risk. The target range is wide, from a low of $113.00 to a high of $230.00, reflecting significant uncertainty about the company's future prospects. The high target of $230.00 suggests some analysts see further upside, while the low target of $113.00 implies a potential 48.5% downside if the company fails to execute on its growth strategy.
Bulls vs Bears: ILMN Investment Factors
Illumina presents a compelling growth story with its dominant market position, robust margins, and strategic push into clinical applications, but the current valuation appears stretched relative to near-term earnings expectations. The bull case is supported by strong operational performance and momentum, while the bear case hinges on decelerating growth and a forward PE that implies earnings decline. The most critical tension is whether the market's optimism about Grail and clinical expansion justifies the premium valuation, or if the stock has run ahead of fundamentals. Currently, the bearish evidence on valuation and growth deceleration slightly outweighs the bullish momentum, suggesting a cautious stance.
Bullish
- Dominant market position in sequencing: Illumina generates over 90% of revenue from sequencing instruments, consumables, and services, maintaining a dominant share in the high-throughput sequencing market. This entrenched position provides pricing power and a recurring revenue stream from consumables, as evidenced by a gross margin of 68.19% in Q1 2026.
- Strong revenue growth and margin expansion: Revenue grew 4.8% YoY in Q1 2026 to $1.091 billion, with gross margin expanding to 68.19% from 65.8% in Q1 2025. Operating margin improved to 21.3% from 17.7% in the same period, reflecting operational leverage and cost discipline.
- Robust free cash flow generation: Free cash flow for the trailing twelve months stands at $989 million, providing ample liquidity for R&D, debt reduction, or strategic investments. This cash generation supports the company's ability to fund its clinical expansion initiatives without diluting shareholders.
- Strategic growth via Grail and clinical applications: The spin-off of Grail and its Galleri multi-cancer screening test represent a high-potential growth avenue, with FDA approval upside and a large addressable market. Despite recent clinical trial setbacks, the long-term opportunity in early cancer detection remains significant, as highlighted by recent analyst commentary.
Bearish
- Valuation appears stretched on forward earnings: The forward PE of 35.99x is significantly higher than the trailing PE of 24.54x, implying that the market expects earnings to decline. This unusual inversion suggests that current earnings may be inflated by one-time items or that analysts anticipate higher expenses, raising concerns about earnings quality.
- Negative PEG ratio signals expected earnings decline: The PEG ratio is -0.14, indicating that earnings growth is expected to be negative. This is a red flag for valuation, as it suggests that the current price already discounts future growth that may not materialize, making the stock vulnerable to de-rating.
- Analyst average target implies downside: The average analyst price target of $198.89 is 9.3% below the current price of $219.40, suggesting that the stock has overshot fundamental estimates. Even the high target of $230.00 offers only 4.8% upside, while the low target of $113.00 implies a potential 48.5% downside.
- Revenue growth decelerating to low single digits: Q1 2026 revenue growth of 4.8% YoY is a significant slowdown from the double-digit growth rates seen in prior years. This deceleration indicates a maturing market and potential saturation in the sequencing space, which could limit future earnings expansion.
ILMN Technical Analysis
Illumina's stock is in a powerful uptrend, with a 1-year price change of +120.97%, significantly outperforming the S&P 500's +20.48% over the same period. The current price of $219.40 is near the top of its 52-week range, sitting at 99.5% of the high of $220.43 and 149.3% above the low of $88.00. This positioning near the highs indicates strong momentum and investor confidence, though it also raises the risk of overextension and a potential pullback.
Beta
1.46
1.46x market volatility
Max Drawdown
-25.7%
Largest decline past year
52-Week Range
$88-$232
Price range past year
Annual Return
+117.4%
Cumulative gain past year
| Period | ILMN Return | S&P 500 |
|---|---|---|
| 1m | +10.7% | +5.5% |
| 3m | +32.3% | +1.7% |
| 6m | +60.3% | +12.2% |
| 1y | +117.4% | +18.6% |
| ytd | +60.5% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ILMN Fundamental Analysis
Illumina's revenue growth has been steady, with the most recent quarter (Q1 2026) showing revenue of $1.091 billion, a 4.8% YoY increase. This growth is modest but consistent, with revenue rising from $1.041 billion in Q1 2025 to $1.091 billion in Q1 2026. The company's gross margin remains robust at 68.19% in Q1 2026, reflecting its strong pricing power and cost management. However, revenue growth has been decelerating from the double-digit rates seen in prior years, indicating a maturing market.
Quarterly Revenue
$1.1B
2026-03
Revenue YoY Growth
+4.8%
YoY Comparison
Gross Margin
68.2%
Latest Quarter
Free Cash Flow
$989000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ILMN Overvalued?
Given Illumina's positive net income, the PE ratio is the most appropriate valuation metric. The trailing PE is 24.54x, while the forward PE is 35.99x, implying that the market expects earnings to decline in the coming year. This is unusual and suggests that the current earnings may be temporarily boosted by one-time items, or that analysts anticipate higher expenses. The PEG ratio is negative at -0.14, indicating that earnings growth is expected to be negative, which is a red flag for valuation.
PE
24.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 7x~161x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Illumina carries a debt-to-equity ratio of 0.94, indicating moderate leverage that could strain cash flows if interest rates rise or earnings falter. The company's net margin of 19.6% is healthy, but the forward PE of 35.99x versus trailing 24.54x suggests that earnings are expected to decline, potentially due to increased R&D spending or competitive pressures. Free cash flow of $989 million provides a cushion, but any significant deterioration in revenue growth could quickly erode investor confidence and lead to multiple compression. Additionally, the negative PEG ratio of -0.14 highlights that the market is pricing in negative earnings growth, which is a fundamental red flag for a stock trading at a premium multiple.
FAQ
The key risks are: 1) Valuation risk, with a forward PE of 35.99x that could compress if earnings disappoint; 2) Clinical risk, as Grail's Galleri test has already failed an NHS trial, and further setbacks could crush the growth narrative; 3) Competitive risk, as emerging sequencing technologies could erode Illumina's dominant market share; 4) Macro risk, with a beta of 1.464 making the stock highly sensitive to market downturns. The most severe risk is a combination of these factors, which could lead to a 48.5% decline to the analyst low target of $113.
The 12-month forecast is mixed. In the base case (50% probability), the stock trades around the analyst average target of $198.89, implying a 9.3% downside. In the bull case (25% probability), the stock could reach $230-$250 if Grail gains FDA approval and revenue growth accelerates. In the bear case (25% probability), the stock could fall to $113-$150 if Grail fails or the market turns. The most likely scenario is the base case, where the stock remains range-bound as investors wait for clearer evidence on Grail's commercial potential.
ILMN is overvalued relative to its own history and peers. The trailing PE of 24.54x is reasonable, but the forward PE of 35.99x implies that the market expects earnings to decline, which is unusual and suggests the current earnings may be inflated. The PS ratio of 4.81x is also high for a company with only 4.8% revenue growth. The market is pricing in significant future growth from Grail and clinical applications, but the negative PEG ratio of -0.14 indicates that this growth is not expected to materialize in the near term, making the stock vulnerable to a de-rating.
ILMN is not a good buy at the current price of $219.40, as the average analyst target of $198.89 implies a 9.3% downside. The stock's forward PE of 35.99x is elevated, and the negative PEG ratio suggests earnings are expected to decline. However, for investors with a long-term horizon who believe in the clinical genomics story, the stock could be a buy on a pullback to the $190-$200 range, where the risk-reward becomes more favorable. The biggest downside risk is a 48.5% drop to the analyst low target of $113 if Grail fails or growth stalls.
ILMN is more suitable for long-term investment, given its high beta of 1.464 and the speculative nature of its Grail growth story. Short-term trading is risky due to the stock's volatility and overextension near its 52-week high. For long-term investors, the company's dominant market position and potential in clinical genomics offer significant upside, but a minimum holding period of 3-5 years is recommended to allow the Grail story to develop. The stock's lack of dividend and high valuation make it unsuitable for income investors.